This randomized controlled trial compared the anticoagulant rivaroxaban to warfarin for preventing stroke in patients with nonvalvular atrial fibrillation. Over 14,000 patients were assigned to either rivaroxaban or warfarin. In the primary analysis, rivaroxaban was found to be noninferior to warfarin in preventing strokes and systemic embolisms. Rivaroxaban was also associated with less intracranial hemorrhaging and fatal bleeding than warfarin. Major bleeding events occurred at a similar rate between the two groups. The study provides evidence that rivaroxaban is a noninferior alternative to warfarin for preventing strokes in patients with atrial fib
Ponencia presentada por la Dra. Vanessa Roldán Schilling en el CardioTV· Live sobre 'Lo mejor en antitrombóticos' celebrado el 25 de noviembre de 2021.
Ponencia presentada por el Dr. J. Raúl Moreno Gómez en el directo 'Controversias en tratamiento antitrombótico – Parte II', realizado el 6 de abril de 2021
XIII Reunión anual de la sección de Insuficiencia Cardiaca de la SEC
OVIEDO, 16-18 JUNIO 2016 HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS (HUCA)
http://secardiologia.es/insuficiencia/cientifico/ic-oviedo-2016
Utilidad de las técnicas de imagen de la insuficiencia cardiaca y trasplante ¿Qué técnica debemos utilizar y qué nos aporta en cada situación clínica?
VIERNES, 17 DE JUNIO 10:30-12:15 SALÓN DE ACTOS
Trasplante cardiaco. ¿Es posible la detección no invasiva del rechazo agudo?
José Antonio Vázquez de Prada, Santander
XIII Reunión anual de la sección de Insuficiencia Cardiaca de la SEC
OVIEDO, 16-18 JUNIO 2016 HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS (HUCA)
http://secardiologia.es/insuficiencia/cientifico/ic-oviedo-2016
¿Qué se recomienda y qué es lo que hacemos?
VIERNES, 17 DE JUNIO 12.45-14.15 SALÓN DE ACTOS
En la prevención y seguimiento de los pacientes en riesgo de cardiotoxicidad
Xavier Bosch Genover, Barcelona
Ponencia presentada por la Dra. Vanessa Roldán Schilling en el CardioTV· Live sobre 'Lo mejor en antitrombóticos' celebrado el 25 de noviembre de 2021.
Ponencia presentada por el Dr. J. Raúl Moreno Gómez en el directo 'Controversias en tratamiento antitrombótico – Parte II', realizado el 6 de abril de 2021
XIII Reunión anual de la sección de Insuficiencia Cardiaca de la SEC
OVIEDO, 16-18 JUNIO 2016 HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS (HUCA)
http://secardiologia.es/insuficiencia/cientifico/ic-oviedo-2016
Utilidad de las técnicas de imagen de la insuficiencia cardiaca y trasplante ¿Qué técnica debemos utilizar y qué nos aporta en cada situación clínica?
VIERNES, 17 DE JUNIO 10:30-12:15 SALÓN DE ACTOS
Trasplante cardiaco. ¿Es posible la detección no invasiva del rechazo agudo?
José Antonio Vázquez de Prada, Santander
XIII Reunión anual de la sección de Insuficiencia Cardiaca de la SEC
OVIEDO, 16-18 JUNIO 2016 HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS (HUCA)
http://secardiologia.es/insuficiencia/cientifico/ic-oviedo-2016
¿Qué se recomienda y qué es lo que hacemos?
VIERNES, 17 DE JUNIO 12.45-14.15 SALÓN DE ACTOS
En la prevención y seguimiento de los pacientes en riesgo de cardiotoxicidad
Xavier Bosch Genover, Barcelona
XIII Reunión anual de la sección de Insuficiencia Cardiaca de la SEC
OVIEDO, 16-18 JUNIO 2016 HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS (HUCA)
http://secardiologia.es/insuficiencia/cientifico/ic-oviedo-2016
Mesa redonda: Novedades en hipertensión pulmonar
VIERNES, 17 DE JUNIO 09:15-10:30 SALÓN DE ACTOS
Nuevas estrategias en el tratamiento de la hipertensión arterial pulmonar. ¿Tienen algún rol en la hipertensión pulmonar del grupo II?
Stepano Ghio, Pavia. Italia
Novedades en el manejo del paciente con FA: actualización tras AHA 2016
22/11/2016 19:30h Casa del Corazón, Madrid
http://manejofa.secardiologia.es
#manejoFA
Pacientes con FA que sufren un SCA y son sometidos a intervención coronaria percutánea. Guías y preguntas abiertas
Dr. Antonio Fernández Ortiz, Hospital Universitario Clínico San Carlos (Madrid)
Novedades en el manejo de la enfermedad cardiovascular en los principales congresos del año 2016
29/11/2016 18:00h Casa del Corazón, Madrid
http://cvvt.secardiologia.es
Perspectiva del cardiólogo clínico
Dr. Domingo Marzal Martín. Complejo Hospitalario de Mérida (Badajoz)
Papel de la Vitamina K en la prevención de los embolismos Hospital Guadix
Reviews en las que se analizan el papel de la vitamina K frente a otros tratamientos en la prevención de los embolismos cerebrales y sintéticos en pacientes con y sin fabricación auricular
Papel de la Vitamina K en la prevención de los embolismosHospital Guadix
Reviews en las que se analizan el papel de la vitamina K frente a otros tratamientos en la prevención de los embolismos cerebrales y sintéticos en pacientes con y sin fabricación auricular
XIII Reunión anual de la sección de Insuficiencia Cardiaca de la SEC
OVIEDO, 16-18 JUNIO 2016 HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS (HUCA)
http://secardiologia.es/insuficiencia/cientifico/ic-oviedo-2016
Mesa redonda: Novedades en hipertensión pulmonar
VIERNES, 17 DE JUNIO 09:15-10:30 SALÓN DE ACTOS
Nuevas estrategias en el tratamiento de la hipertensión arterial pulmonar. ¿Tienen algún rol en la hipertensión pulmonar del grupo II?
Stepano Ghio, Pavia. Italia
Novedades en el manejo del paciente con FA: actualización tras AHA 2016
22/11/2016 19:30h Casa del Corazón, Madrid
http://manejofa.secardiologia.es
#manejoFA
Pacientes con FA que sufren un SCA y son sometidos a intervención coronaria percutánea. Guías y preguntas abiertas
Dr. Antonio Fernández Ortiz, Hospital Universitario Clínico San Carlos (Madrid)
Novedades en el manejo de la enfermedad cardiovascular en los principales congresos del año 2016
29/11/2016 18:00h Casa del Corazón, Madrid
http://cvvt.secardiologia.es
Perspectiva del cardiólogo clínico
Dr. Domingo Marzal Martín. Complejo Hospitalario de Mérida (Badajoz)
Papel de la Vitamina K en la prevención de los embolismos Hospital Guadix
Reviews en las que se analizan el papel de la vitamina K frente a otros tratamientos en la prevención de los embolismos cerebrales y sintéticos en pacientes con y sin fabricación auricular
Papel de la Vitamina K en la prevención de los embolismosHospital Guadix
Reviews en las que se analizan el papel de la vitamina K frente a otros tratamientos en la prevención de los embolismos cerebrales y sintéticos en pacientes con y sin fabricación auricular
Clinical Effectiveness of Dabigatran Versus Apixaban in Non-Valvular Atrial F...Premier Publishers
Many real-world studies conducted across the world revealed that the use of dabigatran and apixaban is similar or superior to warfarin in reducing the risk of stroke and bleeding. But its safety and efficacy in Indian scenario is not that much well established. The aim of this study was to evaluate the clinical outcomes such as ischemic stroke (efficacy end-point) and major bleeding (safety end-point) of dabigatran in clinical practice when compared to apixaban in non-valvular atrial fibrillation real world south Indian patients. Among non-valvular atrial fibrillation patients who initiated dabigatran or apixaban therapy during the period between 2016 and 2018, 82 patients were included in the study. The follow up period was 1 year. Compared to dabigatran group, the hazard ratios of ischemic stroke, major bleeding and minor bleeding in the apixaban group were 0.0031 [95% Confidence Interval (CI): 0.0000-3.2586, P = 0.3363], 1.1108 [CI: 0.0903-13.6604, P=0.9406] and 0.2465 [0.0839-0.7238, P=0.0046] respectively. The ability of dabigatran to prevent ischemic stroke was comparable to that of apixaban; efficacy rate was higher for apixaban and safety outcome was higher for dabigatran. Dabigatran was associated with lower risk of minor bleeding as compared to apixaban. Dabigatran 110 mg bid propound best benefit-risk balance for stroke prevention in non-valvular atrial fibrillation. Dabigatran 150 mg may be favoured for high risk embolism patients.
Stroke prevention for nonvalvular AF, summary of evidence-based guidelinesErsifa Fatimah
Ternyata... guideline yang ngebahas prevensi stroke pada nonvalvular AF tu banyak banget! Yang dirilis komunitas Neuro maupun Cardio, yang internasional maupun yang lokal. Dan pertanyaan besarnya tetep: What's the best strategy?
*Bonus special issue: manajemen prevensi stroke infark dengan antikoagulan pasca brain hemorrhage.
Cancer cell metabolism: special Reference to Lactate PathwayAADYARAJPANDEY1
Normal Cell Metabolism:
Cellular respiration describes the series of steps that cells use to break down sugar and other chemicals to get the energy we need to function.
Energy is stored in the bonds of glucose and when glucose is broken down, much of that energy is released.
Cell utilize energy in the form of ATP.
The first step of respiration is called glycolysis. In a series of steps, glycolysis breaks glucose into two smaller molecules - a chemical called pyruvate. A small amount of ATP is formed during this process.
Most healthy cells continue the breakdown in a second process, called the Kreb's cycle. The Kreb's cycle allows cells to “burn” the pyruvates made in glycolysis to get more ATP.
The last step in the breakdown of glucose is called oxidative phosphorylation (Ox-Phos).
It takes place in specialized cell structures called mitochondria. This process produces a large amount of ATP. Importantly, cells need oxygen to complete oxidative phosphorylation.
If a cell completes only glycolysis, only 2 molecules of ATP are made per glucose. However, if the cell completes the entire respiration process (glycolysis - Kreb's - oxidative phosphorylation), about 36 molecules of ATP are created, giving it much more energy to use.
IN CANCER CELL:
Unlike healthy cells that "burn" the entire molecule of sugar to capture a large amount of energy as ATP, cancer cells are wasteful.
Cancer cells only partially break down sugar molecules. They overuse the first step of respiration, glycolysis. They frequently do not complete the second step, oxidative phosphorylation.
This results in only 2 molecules of ATP per each glucose molecule instead of the 36 or so ATPs healthy cells gain. As a result, cancer cells need to use a lot more sugar molecules to get enough energy to survive.
Unlike healthy cells that "burn" the entire molecule of sugar to capture a large amount of energy as ATP, cancer cells are wasteful.
Cancer cells only partially break down sugar molecules. They overuse the first step of respiration, glycolysis. They frequently do not complete the second step, oxidative phosphorylation.
This results in only 2 molecules of ATP per each glucose molecule instead of the 36 or so ATPs healthy cells gain. As a result, cancer cells need to use a lot more sugar molecules to get enough energy to survive.
introduction to WARBERG PHENOMENA:
WARBURG EFFECT Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside.
Otto Heinrich Warburg (; 8 October 1883 – 1 August 1970) In 1931 was awarded the Nobel Prize in Physiology for his "discovery of the nature and mode of action of the respiratory enzyme.
WARNBURG EFFECT : cancer cells under aerobic (well-oxygenated) conditions to metabolize glucose to lactate (aerobic glycolysis) is known as the Warburg effect. Warburg made the observation that tumor slices consume glucose and secrete lactate at a higher rate than normal tissues.
What is greenhouse gasses and how many gasses are there to affect the Earth.moosaasad1975
What are greenhouse gasses how they affect the earth and its environment what is the future of the environment and earth how the weather and the climate effects.
This pdf is about the Schizophrenia.
For more details visit on YouTube; @SELF-EXPLANATORY;
https://www.youtube.com/channel/UCAiarMZDNhe1A3Rnpr_WkzA/videos
Thanks...!
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Sérgio Sacani
We characterize the earliest galaxy population in the JADES Origins Field (JOF), the deepest
imaging field observed with JWST. We make use of the ancillary Hubble optical images (5 filters
spanning 0.4−0.9µm) and novel JWST images with 14 filters spanning 0.8−5µm, including 7 mediumband filters, and reaching total exposure times of up to 46 hours per filter. We combine all our data
at > 2.3µm to construct an ultradeep image, reaching as deep as ≈ 31.4 AB mag in the stack and
30.3-31.0 AB mag (5σ, r = 0.1” circular aperture) in individual filters. We measure photometric
redshifts and use robust selection criteria to identify a sample of eight galaxy candidates at redshifts
z = 11.5 − 15. These objects show compact half-light radii of R1/2 ∼ 50 − 200pc, stellar masses of
M⋆ ∼ 107−108M⊙, and star-formation rates of SFR ∼ 0.1−1 M⊙ yr−1
. Our search finds no candidates
at 15 < z < 20, placing upper limits at these redshifts. We develop a forward modeling approach to
infer the properties of the evolving luminosity function without binning in redshift or luminosity that
marginalizes over the photometric redshift uncertainty of our candidate galaxies and incorporates the
impact of non-detections. We find a z = 12 luminosity function in good agreement with prior results,
and that the luminosity function normalization and UV luminosity density decline by a factor of ∼ 2.5
from z = 12 to z = 14. We discuss the possible implications of our results in the context of theoretical
models for evolution of the dark matter halo mass function.
A brief information about the SCOP protein database used in bioinformatics.
The Structural Classification of Proteins (SCOP) database is a comprehensive and authoritative resource for the structural and evolutionary relationships of proteins. It provides a detailed and curated classification of protein structures, grouping them into families, superfamilies, and folds based on their structural and sequence similarities.
Seminar of U.V. Spectroscopy by SAMIR PANDASAMIR PANDA
Spectroscopy is a branch of science dealing the study of interaction of electromagnetic radiation with matter.
Ultraviolet-visible spectroscopy refers to absorption spectroscopy or reflect spectroscopy in the UV-VIS spectral region.
Ultraviolet-visible spectroscopy is an analytical method that can measure the amount of light received by the analyte.